Tesaglitazar
Tesaglitazar is a pharmaceutical drug that was developed by AstraZeneca for the treatment of Type 2 diabetes. It belongs to the class of drugs known as glitazones, which are used to lower blood sugar levels in patients with Type 2 diabetes. However, the development of Tesaglitazar was discontinued in 2006 due to concerns about its safety profile.
History[edit | edit source]
Tesaglitazar was first synthesized by AstraZeneca in the early 2000s as part of their research into new treatments for Type 2 diabetes. The drug was designed to act as a dual PPAR agonist, stimulating both the alpha and gamma forms of the Peroxisome proliferator-activated receptor (PPAR). This dual action was expected to provide better control of blood sugar levels than existing treatments, which typically targeted only one form of the receptor.
In 2006, however, AstraZeneca announced that it was discontinuing the development of Tesaglitazar. This decision was based on data from clinical trials, which suggested that the drug might increase the risk of heart disease and kidney damage. The company concluded that the potential benefits of the drug did not outweigh these risks.
Mechanism of Action[edit | edit source]
Tesaglitazar acts as a dual PPAR agonist, stimulating both the alpha and gamma forms of the PPAR. The alpha form of the receptor is primarily involved in the regulation of lipid metabolism, while the gamma form is involved in the regulation of glucose metabolism. By stimulating both forms of the receptor, Tesaglitazar was expected to provide better control of blood sugar levels than existing treatments.
Clinical Trials[edit | edit source]
Several clinical trials were conducted to evaluate the safety and efficacy of Tesaglitazar. These trials showed that the drug was effective in lowering blood sugar levels in patients with Type 2 diabetes. However, they also suggested that the drug might increase the risk of heart disease and kidney damage. These findings led to the decision to discontinue the development of the drug.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
